In a decision earlier this year related to the 180 day exclusivity determination for the generic player Teva for its generic granisetron injection. The decision highlights some holes in Modernisation Medicare Amendments Act 2003. The parking of exclusivity is still possible as per that ruling.
The final decision for this can be read here.
I welcome comments on this topic as this is debatable at the IP front.
No comments:
Post a Comment